• HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
Monday, December 4, 2023
BIOENGINEER.ORG
No Result
View All Result
  • Login
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
  • HOME
  • NEWS
  • EXPLORE
    • CAREER
      • Companies
      • Jobs
        • Lecturer
        • PhD Studentship
        • Postdoc
        • Research Assistant
    • EVENTS
    • iGEM
      • News
      • Team
    • PHOTOS
    • VIDEO
    • WIKI
  • BLOG
  • COMMUNITY
    • FACEBOOK
    • INSTAGRAM
    • TWITTER
  • CONTACT US
No Result
View All Result
Bioengineer.org
No Result
View All Result
Home NEWS Science News Health

COVID-19 vaccine gives substantial protection against reinfection

Bioengineer by Bioengineer
November 22, 2022
in Health
Reading Time: 3 mins read
0
Share on FacebookShare on TwitterShare on LinkedinShare on RedditShare on Telegram

Individuals previously infected with SARS-CoV-2, the virus that causes COVID-19, still benefit from vaccination, gaining 60% to 94% protection against reinfection, depending on the variant. A new study led by Katrine Finderup Nielsen at Statens Serum Institut, Denmark, reports these findings November 22nd in the open access journal PLOS Medicine.

COVID-19 vaccine gives substantial protection against reinfection

Credit: Hakan Nural, Unsplash (CC0, https://creativecommons.org/publicdomain/zero/1.0/)

Individuals previously infected with SARS-CoV-2, the virus that causes COVID-19, still benefit from vaccination, gaining 60% to 94% protection against reinfection, depending on the variant. A new study led by Katrine Finderup Nielsen at Statens Serum Institut, Denmark, reports these findings November 22nd in the open access journal PLOS Medicine.

During the recent pandemic, vaccination has been one of the best tools available for curbing the spread of COVID-19. People infected with the virus are known to develop long-lasting natural immunity, but Finderup Nielsen and her team wanted to know whether these individuals would still benefit from receiving the vaccine. The team analyzed infection and vaccination data from nationwide Danish registers that included all people living in Denmark who tested positive for the virus or were vaccinated between January 2020 and January 2022. The data set included more than 200,000 people who tested positive for SARS-CoV-2 during each of the Alpha, Delta and Omicron waves. Their analysis showed that for people with previous infections, vaccination offered up to 71% protection against reinfection during the Alpha period, 94% during the Delta period and 60% during the Omicron period, with protection lasting up to nine months.

These findings show vaccination protected people against SARS-CoV-2, over and above the protection offered by natural immunity during all three waves of variants. The authors point out that the current study was too short to determine whether the vaccine protects against severe outcomes, such as death and hospitalization, and that future studies with longer follow-up times will be necessary to answer this question. From a public health perspective, these insight into vaccine effectiveness can help decision makers plan the timing and execution of vaccination strategies to make them most effective.

Finderup Nielsen adds, “In our study we find a significant vaccine effectiveness against SARS-CoV-2 reinfection, and this shows the importance of vaccination also for those who might be protected by natural immunity.”

#####

In your coverage, please use this URL to provide access to the freely available paper in PLOS Medicine: http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1004037

Citation: Nielsen KF, Moustsen-Helms IR, Schelde AB, Gram MA, Emborg H-D, Nielsen J, et al. (2022) Vaccine effectiveness against SARS-CoV-2 reinfection during periods of Alpha, Delta, or Omicron dominance: A Danish nationwide study. PLoS Med 19(11): e1004037. https://doi.org/10.1371/journal.pmed.1004037

Author Countries: Denmark

Funding: The author(s) received no specific funding for this work.



Journal

PLoS Medicine

DOI

10.1371/journal.pmed.1004037

Method of Research

Observational study

Subject of Research

People

COI Statement

Competing interests: The authors have declared that no competing interests exist.

Share12Tweet8Share2ShareShareShare2

Related Posts

Immune cells producing IL-17

Immune protein may induce dementia unrelated to high blood pressure

December 4, 2023
Significant rise in eating disorder hospitalizations among boys, young teens, and those with 'atypical' diagnoses

Eating disorder hospitalizations on the rise, affecting ‘atypical’ groups the most

December 4, 2023

Salty immune cells surrounding the brain linked to hypertension-induced dementia

December 4, 2023

What’s behind the holiday-suicide myth

December 4, 2023

POPULAR NEWS

  • Figure 1

    Understanding rapid tendon regeneration in newts may one day help human athletes

    85 shares
    Share 34 Tweet 21
  • Study finds increasingly popular oral nicotine pouches do little to curb smokers’ cravings

    35 shares
    Share 14 Tweet 9
  • SMART researchers pioneer novel microfluidic method to optimise bone marrow stem cell extraction for advanced cell therapies

    34 shares
    Share 14 Tweet 9
  • UMass Amherst receives $2.5 million from Howard Hughes Medical Institute to reshape STEM education

    34 shares
    Share 14 Tweet 9

About

We bring you the latest biotechnology news from best research centers and universities around the world. Check our website.

Follow us

Recent News

Leukemia cells activate cellular recycling program

Mathematics supporting fresh theoretical approach in oncology

Georgia State professor granted $5 million to identify and characterize objects in space

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 58 other subscribers
  • Contact Us

Bioengineer.org © Copyright 2023 All Rights Reserved.

No Result
View All Result
  • Homepages
    • Home Page 1
    • Home Page 2
  • News
  • National
  • Business
  • Health
  • Lifestyle
  • Science

Bioengineer.org © Copyright 2023 All Rights Reserved.

Welcome Back!

Login to your account below

Forgotten Password?

Retrieve your password

Please enter your username or email address to reset your password.

Log In